ONLINE EXCLUSIVE
Molecular Profiling and Decision Making
in Breast Cancer:
A Continual Online Learning Series
Four programs addressing the use of molecular profiling
and decision making in breast cancer
Treatment Decision Tools
Hope S. Rugo, MD; Eleftherios Mamounas, MD
Moderator: Debu Tripathy, MD
Applications in the Clinical Setting
David M. Euhus, MD, FACS; Stephen Johnston, MD, PhD
Moderator: Debu Tripathy, MD
Defining Candidates for Gene Profiling
Charles Perou, PhD
Lori Goldstein, MD
Matthew Ellis, MB BChir, FRCP
Moderator: Debu Tripathy, MD
Clinical and Molecular Prognostic Information: Addressing Discordant Results
Hope S. Rugo, MD; Eleftherios Mamounas, MD; David M. Euhus, MD, FACS; Stephen Johnston, MD, PhD; Charles Perou, PhD; Lori Goldstein, MD
Moderator: Debu Tripathy, MD
This continual online learning series consists of four programs addressing the use of molecular profiling and decision making in breast cancer. Rapid changes in the understanding of the molecular diversity of breast and other cancers has been enabled by new gene profiling technology. Gene signatures using defined platforms and algorithms can provide more accurate estimations of long term prognosis of early stage breast cancer compared to standard clinical and pathological indices. Expert researchers and clinicians will offer didactic overviews of the scientific basis and technology, reviews of landmark clinical studies, case-based learning opportunities and a panel discussion.
Molecular Profiling and Decision Making in Breast Cancer: A Continual On-Line Learning Series is designed to provide sustained on-line learning for oncologists and other health care providers involved in the diagnosis and treatment of breast cancer. In the area of molecular profiling the recent emergence of commercially available gene profiling tools, coupled with the variable degree of benefit balanced against the short and long term effects of chemotherapy creates a pressing educational need for clinicians.
Medical and surgical oncologists who counsel patients on therapeutic decisions following surgery for early stage breast cancer. Other physicians such as radiation oncologists, primary physicians, and healthcare providers such as nurses, pharmacists and others who care for patients with breast cancer.
At the conclusion of this activity, you should be able to:
An educational grant for this activity was provided by:
Agendia
Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. (Each program is designated for a maximum of 0.5 AMA PRA Category 1 Credits™. The total for the series is 2 AMA PRA Category 1 Credits™.)
Certificates will be provided after the successful completion of each module.